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Background
The effect of Timothy grass AIT treatment on a Canadian
subpopulation was assessed post-hoc using data from 2
randomized, double-blind, trials designed to evaluate grass
AIT in North American subjects.
Methods
Subjects 5 years and older with ARC with/without asthma
received once-daily 2800 BAU sublingual grass AIT (oral
lyophilisate, Phleum pratense, 75,000 SQ-T, ~15μg Phl p5)
or placebo starting approximately 16 weeks before and
continuing throughout the 2009 grass pollen season
(GPS). Subjects used daily e-diaries to record ARC symp-
toms and use of symptomatic medications from randomi-
zation through study end (approximately 24 weeks). The
primary efficacy endpoint comprised the average total
combined daily symptom and medication score (TCS)
during the entire GPS. Secondary endpoints included aver-
age daily symptom score (DSS) and average daily medica-
tion score (DMS). Safety was assessed by monitoring
adverse events (AEs).
Results
The Canadian subpopulation included 103 subjects (46
pediatric [5-17y]; 57 adult [18-65y]). AIT-treated subjects
showed reductions, vs placebo, of 38% (P=.016) for entire
and 45% (P=.005) for peak seasons in TCS; of 38%
(P=.013) for entire and 40% (P=.008) for peak seasons in
DSS; and of 39% for entire (P=.238) and 60% (P=.005) for
peak seasons in DMS. Among the overall population,
most treatment-related AEs were mild or moderate. No
serious or life-threatening treatment-related AEs
occurred; no new safety concerns emerged.
Conclusions
Timothy grass AIT, a novel therapeutic modality, signifi-
cantly improved ARC caused by Timothy grass pollen and
related grasses in Canadian adults and children 5 years
and older.
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